Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Pockros

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Hospital Practice (Office Ed.)|May 1, 1983
Persistent abnormal liver function without clinical signs or symptomsP Pockros, W S Haubrich
Transplantation|March 1, 1993
Systemic versus nonsystemic reperfusion of the transplanted liverJ J Brems, H Takiff, J McHutchison, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2010
Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis CM L Shiffman, P Pockros, J G McHutchison, et al.
Hepatology (Baltimore, Md.)|August 26, 1999
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study GroupK R Reddy, J H Hoofnagle, M J Tong, et al.
Clinical Therapeutics|September 18, 2001
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunctionG M Ferron, R A Preston, R J Noveck, et al.
Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
Blood Cells, Molecules & Diseases|January 1, 1996
Mutation analysis in hereditary hemochromatosisE Beutler, T Gelbart, C West, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Hospital Practice (Office Ed.)|May 1, 1983
Persistent abnormal liver function without clinical signs or symptomsP Pockros, W S Haubrich
Transplantation|March 1, 1993
Systemic versus nonsystemic reperfusion of the transplanted liverJ J Brems, H Takiff, J McHutchison, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2010
Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis CM L Shiffman, P Pockros, J G McHutchison, et al.
Hepatology (Baltimore, Md.)|August 26, 1999
Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study GroupK R Reddy, J H Hoofnagle, M J Tong, et al.
Clinical Therapeutics|September 18, 2001
Pharmacokinetics of pantoprazole in patients with moderate and severe hepatic dysfunctionG M Ferron, R A Preston, R J Noveck, et al.
Journal of Viral Hepatitis|October 10, 2012
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirinS Zeuzem, M Rodríguez-Torres, K Rajender Reddy, et al.
Blood Cells, Molecules & Diseases|January 1, 1996
Mutation analysis in hereditary hemochromatosisE Beutler, T Gelbart, C West, et al.
Pageof 1